What Are Radiopharmaceuticals and How Are They Used in Cancer?

Written by: Dana-Farber Staff

Key Takeaways:

  • Radiopharmaceuticals can be used to diagnose and treat certain types of cancer. 
  • Radiopharmaceuticals are sometimes called radioligand therapies (RLT). 
  • Researchers are increasingly interested in the potential of radiopharmaceutical agents to target more types of cancer. 

Drugs that contain radioactive isotopes — forms of chemical elements that emit radiation — are known as radiopharmaceuticals. Radioisotopes have been used to treat cancer as far back as the 1940s, but the field has really taken off just in the past few years as researchers explore their potential in cancer. 

How are radiopharmaceuticals used in cancer today? 

Because they give off carefully controlled amounts of radiation, radiopharmaceuticals can be injected into the body and viewed with imaging devices as they bind to specific molecules on the surface of cancer cells to aid in a cancer diagnosis. This process is called theranostics. 

Radiopharmaceuticals, sometimes called radioligand therapies (RLT), are also used to deliver cell-killing doses of radiation directly to cancer cells within the body. 

Radiopharmaceuticals consist of a radioactive molecule, a targeting molecule, and a linker that joins the two.
Radiopharmaceuticals consist of a radioactive molecule, a targeting molecule, and a linker that joins the two.

In 2013, a drug known as Xofigo, or radium 223 dichloride, was approved to treat metastatic prostate cancer that has spread to the bones. Radium 223 dichloride is absorbed into the bones, and the radiation it emits kills cancers cells there. It does not cure cancer, but helps to shrink bone metastases and relieve bone pain and may help people with metastatic prostate cancer live longer. 

More recent therapeutics involve radioisotopes that are linked to antibodies, peptides (building blocks of proteins), or small molecules that target specific proteins expressed on the surface of tumor cells, but not on normal cells. In 2018 the drug lutetium Lu 177-dotatate, or Lutathera, was approved to treat certain cancerous neuroendocrine tumors affecting the digestive tract. The drug’s approval was hailed as a big step forward in the field: It showed that solid tumors could be effectively targeted with cell-killing radiation from radioisotope linked to peptides that latched onto a cancer-specific target on tumor cells. 

More recently, the drug lutetium Lu 177 vipivotide tetraxetan, or Pluvicto, was approved to treat prostate cancer. It can be used to treat PSMA-positive metastatic hormone-sensitive prostate cancer, metastatic castration-resistant prostate cancer after androgen therapy, or after chemotherapy.   

There is “an explosion of companies that are looking at different radiopharmaceutical agents targeting cancer,” says Heather Jacene, MD, clinical director of Nuclear Medicine in the Department of Imaging. 

What’s the latest research in radiopharmaceuticals? 

Current research related to radiopharmaceuticals focuses on three areas: 

  • Moving radiopharmaceuticals that prove to be effective for relapsed metastatic cancers into earlier lines of treatment, including newly diagnosed metastatic disease. 
  • Combining radiopharmaceuticals with other therapies to potentially enhance their ant-cancer effects. 
  • Developing new radiopharmaceuticals that either use different isotopes with different qualities or different approaches to targeting cancer. 

Novel radiopharmaceuticals and combination therapies involving radiopharmaceuticals are being tested in clinical trials at Dana-Farber. For example: 

  • Trials of Pluvicto and Xofigo for patients with kidney cancer. 
  • Trials of novel radiopharmaceuticals for patients with metastatic solid tumors. 

Learn more about clinical trials of radioligand therapies at Dana-Farber.  

Are radiopharmaceuticals safe?

Patients may naturally be concerned about the safety of having radioactive substances administered to them. But the scientific evidence indicates that the risks associated with exposure to diagnostic nuclear medicine are minimal, and use of radiopharmaceutical tracers often eliminates the need for invasive procedures or surgery. The risks associated with therapeutic nuclear medicine are higher, but the benefits are potentially lifesaving, say researchers. 

Treatment with radiopharmaceuticals requires teamwork, including nuclear medicine experts like Jacene, and rooms equipped for administering therapeutic radiopharmaceuticals to protect the staff; Dana-Farber has one at its main campus and a two-room suite at its Chestnut Hill facility. 

4 thoughts on “What Are Radiopharmaceuticals and How Are They Used in Cancer?”

  1. I had PRRT – Lutethera Dotatate therapy four times throughout 2020 and it worked very well for me. It arrested the growth of more neuroendocrine cancer cells in my liver and abdominal cavity. It was definitely worth having this life-changing therapy!

Comments are closed.